title: Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins.
abstract: OBJECTIVE
  Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers.
  
  
  METHODS
  Electroneurographic assessments with surface electrodes were performed after single injections of NT 201 (2, 4, 16, or 32 units) into the extensor digitorum brevis (EDB) muscle and the same dose (Botox; Allergan Pharmaceuticals (Ireland) Ltd. Westport, Ireland) into the contralateral EDB.
  
  
  RESULTS
  All NT 201 and BTXCo doses achieved a statistically significant reduction of the compound muscle action potential M-wave amplitude in the EDB muscle. At week 4, the highest dose was statistically significantly more effective than the lowest dose (NT 201, P = 0.019; 95% confidence interval, 0.195-1.370; and BTXCo, P = 0.002; 95% confidence interval, 0.309-1.167). Duration of effect was dose dependent. The mean values of compound muscle action potential M-wave amplitudes in the adjacent muscles (abductor digiti quinti and abductor hallucis) were above the predefined threshold of effect, indicating that there was no relevant diffusion-induced reduction of muscle activity. NT 201 and BTXCo were well tolerated.
  
  
  CONCLUSIONS
  NT 201 is effective and safe in inducing the desired paretic effect.
authors.affiliation: Humaine Klinikum Bad Saarow, Germany.
authors.forename: Kai
authors.initials: K
authors.lastname: Wohlfarth
authors.forename: Christian
authors.initials: C
authors.lastname: Müller
authors.forename: Irena
authors.initials: I
authors.lastname: Sassin
authors.forename: Georg
authors.initials: G
authors.lastname: Comes
authors.forename: Susanne
authors.initials: S
authors.lastname: Grafe
mesh_terms: D000200:Action Potentials / Q000187:drug effects*; D000293:Adolescent; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000494:pharmacology*; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004576:Electromyography; D005500:Follow-Up Studies; D007839:Functional Laterality; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D018482:Muscle, Skeletal / Q000187:drug effects*; D009498:Neurotoxins / Q000494:pharmacology*
chemical_list: D009498:Neurotoxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA